D. Thai

发表

Evaluation of intratumoral T cells in biopsies from advanced gastric cancer patients treated with andecaliximab and nivolumab.

M. Shah, E. Van Cutsem, Z. Wainberg, 2019, Journal of Clinical Oncology.

A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.

M. Shah, Z. Wainberg, D. Cunningham, 2017, Journal of Clinical Oncology.

Exploratory evaluation of baseline tumor biomarkers and their association with response and survival in patients with previously treated advanced gastric cancer treated with andecaliximab combined with nivolumab versus nivolumab.

M. Shah, E. Van Cutsem, Z. Wainberg, 2019, Journal of Clinical Oncology.

Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction

G. Lopaschuk, G. Oudit, Qutuba G. Karwi, 2019, Cardiovascular Diabetology.

A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma

K. Muro, K. Chìn, D. Sakai, 2022, Scientific Reports.

Glucagon Receptor Antagonism Ameliorates Progression of Heart Failure

Hai Yan, Yibin Wang, Chen Gao, 2019, JACC. Basic to translational science.

Glucagon Receptor Antagonism Improves Glucose Metabolism and Cardiac Function by Promoting AMP-Mediated Protein Kinase in Diabetic Mice

J. McDonald, R. Unger, May-yun Wang, 2018, Cell reports.

Antagonistic Glucagon Receptor Antibody Promotes α-Cell Proliferation and Increases β-Cell Mass in Diabetic Mice

Kun Yang, Hai-ning Wang, R. Wei, 2019, iScience.

Safety and Ef ﬁ cacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study

Manish, J. Berlin, Sunil Sharma, 2020 .

Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial

J. Rosenstock, S. Garg, T. Bailey, 2022, Nature Medicine.

Comparative pharmacokinetics and tissue distribution of the d-enantiomers of para-substituted methylphenidate analogs.

J. Perel, D. Thai, G. Rudolph, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.

J. Berlin, M. Shah, Sunil Sharma, 2020, The oncologist.

Synthesis of Carbacephems from Serine

H. Rapoport, D. Thai, J. J. Folmer, 1998 .

Synthesis of Carbacephems from Serine.

H. Rapoport, D. Thai, J. J. Folmer, 1999 .

Asymmetric synthesis and pharmacology of methylphenidate and its para-substituted derivatives.

D. Bierer, J. Perel, D. Thai, 1998, Journal of medicinal chemistry.

Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)

J. Ajani, M. Shah, G. Bodoky, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival

M. Shah, E. Van Cutsem, Z. Wainberg, 2021, Journal for ImmunoTherapy of Cancer.

Phase I study of GS-5745 alone and in combination with chemotherapy in patients with advanced solid tumors.

M. Shah, Z. Wainberg, J. Bendell, 2015 .

Effect of a glucagon receptor antibody (REMD‐477) in type 1 diabetes: A randomized controlled trial

D. Reeds, S. Klein, R. Henry, 2018, Diabetes, obesity & metabolism.

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).

J. Ajani, M. Shah, G. Bodoky, 2019, Journal of Clinical Oncology.

618PDA PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF SIMTUZUMAB OR PLACEBO IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PANCREATIC ADENOCARCINOMA.

A. Benson, Z. Wainberg, J. Bendell, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II, randomized, double-blinded, placebo-controlled study of simtuzumab or placebo in combination with FOLFIRI for the second line treatment of metastatic KRAS mutant colorectal adenocarcinoma.

J. Hecht, J. Bendell, K. Bencardino, 2015 .

Phase I and IIa studies of simtuzumab alone and in combination with FOLFIRI in patients with advanced solid tumors.

J. Hecht, A. Tolcher, P. LoRusso, 2014 .

Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition

H. Lyerly, M. Morse, F. Calzone, 2021, Leukemia & lymphoma.

P505: SAFETY AND EFFICACY OF CASEIN KINASE 1Α AND CYCLIN DEPENDENT KINASE 7/9 INHIBITION IN PATIENTS WITH RELAPSED OR REFRACTORY AML: A PHASE 1, FIRST-IN-HUMAN STUDY OF BTX-A51

D. Thai, G. Borthakur, B. J. Ball, 2022, HemaSphere.

Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors

L. Lad, D. Thai, S. Deva, 2024, Journal for ImmunoTherapy of Cancer.